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Dipeptidyl peptidase (DPP-4) inhibitors (“gliptins”) are increasingly used in type 2 
diabetes mellitus (T2DM) for treating hyperglycaemia. They offer the advantage of improving 
glucose control without weight gain and with a minimal risk of hypoglycaemia1. Randomised 
controlled trials have proven their efficacy and safety as monotherapy in patients on diet and 
exercise, as dual therapy in add-on to metformin, sulphonylurea, thiazolidinedione or insulin and 
in various triple therapies1. Commercialized DPP-4 inhibitors are used in once-daily 
administration (sitagliptin, saxagliptin, alogliptin, linagliptin), except vildagliptin that is given 
twice daily in absence of renal impairment. 
Inagaki and colleagues report in the Lancet Diabetes Endocrinology the results of a first 
24-week trial comparing the efficacy and safety profile of a once-weekly DPP-4 inhibitor 
(trelagliptin) with that of the once-daily DPP-4 inhibitor alogliptin in Japanese patients with 
T2DM treated with diet and exercise2. The study demonstrates that trelagliptin 100 mg once 
weekly is significantly more effective than placebo and non-inferior to alogliptin 25 mg once 
daily in terms of reduction in glycated haemoglobin (HbA1c). The tolerance/safety profile 
was good and similar with the two DPP-4 inhibitors. These data should be confirmed in 
combined therapy, especially in patients not well controlled with metformin3.  The comparator 
used in this Japanese study was alogliptin 25 mg whereas, in most comparative studies, the 
DPP-4 inhibitor used as reference is sitagliptin 100 mg. Although the two once daily DPP-4 
inhibitors appear to have a comparable efficacy, no head-to-head trial compared alogliptin and 
sitagliptin. In a mixed treatment comparison of randomised controlled trials, the weighted 
absolute HbA1c change from baseline averaged -0.58% (95% confidence interval or CI -0.83, 
-0.33) with alogliptin and -0.59% (-0.75, -0.43) with sitagliptin4. In fact, rather few studies 
directly compared the efficacy of two different DPP-4 inhibitors4. In patients with T2DM 
inadequately controlled by metformin alone, saxagliptin 5 mg was noninferior to sitagliptin 
100 mg regarding the reduction in HbA1c, although sitagliptin exerted a slightly stronger 
effect on fasting glucose than saxagliptin5, probably because of a more prolonged inhibition 
of DPP-4 enzyme6. Vildagliptin 50 mg twice daily was also associated with a more sustained 
DPP-4 inhibition over 24 hours, which may contribute to a better control of fasting glucose 
levels6. Here, the reduction in fasting plasma glucose was lower with trelagliptin once weekly 
than with alogliptin once daily (-0.36 versus -0.83 mmol/l; point estimate 0.48, 95% CI 0.095, 
0.858)2. A detailed comparison of the kinetics of DPP-4 inhibition with the two compounds 
would be of interest. 
MK-3102 (omarigliptin) is another potent and selective DPP-4 inhibitor with an 
excellent pharmacokinetic profile amenable for once-weekly human dosing7.  A 24-week 
head-to-head trial (reported  as abstract only) compared the efficacy of omarigliptin 25 mg once 
weekly with sitagliptin 50 mg once daily (the classical dose used in Japan) and with placebo in 
Japanese patients with T2DM 8. This study also reported better efficacy of omarigliptin once 
weekly than placebo and non-inferiority versus sitagliptin once daily (Table 1). The results of 
these two studies obtained in Japanese patients should be replicated in other ethnic groups, 
especially because DPP-4 inhibitors were shown to exhibit a better glucose-lowering efficacy 
in Asian than in Caucasian people and because doses of DPP-4 inhibitors may also differ9. 
Treatment of hyperglycaemia in T2DM with once weekly therapy started with the 
development of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. Extended-
release exenatide was the first one commercialized but several others are now available or in 
late phase of development (dulaglutide, albiglutide, semaglutide)10. They have a better 
gastrointestinal tolerance and should improve ease of use and patient’s compliance compared 
with once or twice daily GLP-1 receptor agonists. Whereas the advantage of a once-weekly 
administration appears obvious for an injectable compound, it is less evident for orally 
administered medications such as DPP-4 inhibitors. Nevertheless, a majority of patients with 
T2DM require numerous drugs to tackle hyperglycaemia, hypertension, dyslipidaemia and 
other comorbidities. Thus, although questions remain over the extent to which once-weekly 
DPP-4 inhibitor administration is an unmet need, simplifying therapy may be well received 
from a patient perspective at a time when a patient-centered approach is recommended for the 
management of T2DM. Further real-life studies should demonstrate whether once-weekly 
DPP-4 inhibitors may contribute to improve patient’s satisfaction and compliance and as a 
consequence help to better and safely control T2DM on a long-term basis. 
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Table 1 : Comparison of the results of to head-to-head 24-week trials comparing the efficacy 
of a once-weekly DPP-4 inhibitor with that of a once-daily DPP-4 inhibitor in Japanese 
patients treated with diet and exercise. 
 
n ∆ HbA1c % 
∆ FPG 
mmol/l 







Inagaki et al 20142 
Placebo 50 +0.24 -0.31 -0.12 4.3 
Alogliptin 25 mg 
once daily 92 -0.46 -0.83 -1.62 36.1 
Tetragliptin 100mg 






   
Gantz et al 20148 
Placebo 82 +0.13 -0.35 -0.30 7.3 
Sitagliptin 50 mg 
once daily 164 -0.65 -1.15 -2.51 37.8 
Omarigliptin 25mg 
once weekly 166 -0.66 -1.03 -2.35 47.0 
 LSMD -0.02% (-0.15, 0.12)    
 
 
CI : confidence interval. Δ : change versus baseline FPG : fasting plasma glucose. HbA1c : 
glycated haemoglobin. LSMD : Least square mean difference (once-weekly versus once-daily 
administration). 
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